(NASDAQ: ACRS) Aclaris Therapeutics's forecast annual revenue growth rate of -31.45% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.32%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.67%.
Aclaris Therapeutics's revenue in 2025 is $17,778,000.On average, 5 Wall Street analysts forecast ACRS's revenue for 2025 to be $691,917,117, with the lowest ACRS revenue forecast at $563,062,443, and the highest ACRS revenue forecast at $779,624,921. On average, 5 Wall Street analysts forecast ACRS's revenue for 2026 to be $621,750,874, with the lowest ACRS revenue forecast at $97,453,115, and the highest ACRS revenue forecast at $1,082,812,390.
In 2027, ACRS is forecast to generate $642,757,435 in revenue, with the lowest revenue forecast at $433,124,956 and the highest revenue forecast at $769,879,609.